38281-49-1Relevant articles and documents
Gold(I)-catalyzed endo-selective intramolecular α-alkenylation of β-yne-furans: Synthesis of seven-membered-ring-fused furans and dft calculations
Dong, Zhe,Liu, Cheng-Hang,Wang, Yi,Lin, Mu,Yu, Zhi-Xiang
, p. 14157 - 14161 (2013)
Alkenylation of furans: An efficient gold-catalyzed endo-selective intramolecular α-alkenylation of β-alkyne-substituted furans has been developed to synthesize challenging seven-membered-ring-fused furans in good to excellent yields. Preliminary DFT calc
A carboxylate-assisted amination/unactivated C(sp2)-H arylation reactionviaa palladium/norbornene cooperative catalysis
An, Yang,Zhang, Bo-Sheng,Zhang, Zhe,Liu, Ce,Gou, Xue-Ya,Ding, Ya-Nan,Liang, Yong-Min
supporting information, p. 5933 - 5936 (2020/06/04)
This report describes a carboxylate-assisted palladium-catalysed Catellani reaction, which is compatible withortho-amination and unactivated C(sp2)-H arylation. This method was used to synthesize a series of 1-amino substituted dihydrophenanthridines, phenanthridines and 6H-benzo[c]chromenes. Based on kinetic isotope experiments, the kinetic curve proves that pivalic acid accelerates the reaction rate of unactivated C(sp2)-H activation, and thus this rate can keep up with the five membered aryl-norbornene-palladacycle (ANP) intermediate.
Mercapto-amide boronic acid derivative and application thereof as MBL (metal beta-lactamase) and/or SBL (serine beta-lactamase) inhibitor
-
Paragraph 0090; 0091; 0100; 0101, (2019/09/14)
The invention provides a compound of a formula (I) shown in the specification, or a conformational isomer, or an optical isomer or a pharmaceutically acceptable salt thereof. The compound of the formula (I) shown in the specification has excellent broad-spectrum inhibitory activity on MBL (metal beta-lactamase) and/or SBL (serine beta-lactamase), and can be used for preparing MBL and/or SBL inhibitors. Moreover, the compound disclosed by the invention has excellent antibacterial activity on multiple drug-resistant bacteria and is capable of reversing drug resistance of carbapenem drug-resistant bacteria, and the antibacterial effect of the compound is prior to those of positive control products such as L-captopril and tazobactam. The compound disclosed by the invention has very great potential in preparation of MBL/SBL dual inhibitors and medicines reversing drug resistance of carbapenem drug-resistance bacteria.